Zhao Lina, Zhou Yongchun, Pan Haitao, Yin Yutian, Chai Guangjin, Mu Yunfeng, Xiao Feng, Lin Steven H, Shi Mei
Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, No. 127 West Changle Road, Xi'an, 710032 China.
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030.
J Cancer. 2017 Sep 15;8(16):3242-3250. doi: 10.7150/jca.20835. eCollection 2017.
The reported data of elderly ESCC are rather limited and there is a lack of information to guide treatment decisions for elderly patients with esophageal cancer. This study aims to identify the efficacy and factors for optimal treatment approaches for elderly esophageal squamous cell carcinoma (ESCC) treated with radiotherapy (RT) alone or concurrent chemoradiation (CCRT). This study included 184 I-III elderly ESCC patients aged ≥70 years treated by oral single agent CCRT (sCCRT) or double agents CCRT (dCCRT) or RT alone at a single institution in China. RT was delivered with Intensity Modulated Irradiation Therapy (IMRT) or Volumetric-Modulated Arc Therapy (VMAT). Sequential or simultaneous integrated boost (SIB) approach was applied for GTV dose escalation. Toxicities were evaluated by criteria of Radiation Therapy Oncology Group. Statistical analyses were performed on survival and failure patterns. At a median follow-up time of 15.5 months, the 2- and 3-year estimated overall survival (OS) were 43.5% and 35.2%, respectively. T and N stage, GTV dose (cutoff value 56Gy), simultaneous integrated boost (SIB) technique and CCRT were significant predictors for the outcomes. sCCRT was significantly associated with higher OS, LRFS, and DFS when compared with RT alone and no difference was observed between sCCRT and dCCRT. 44% patients experienced treatment failure, among whom 65.4% developed local failure. 81.3% local failure occurred in GTV and 70.6% regional failures occurred out of radiation field. dCCRT was the only independent prediction factor for grade ≥ 2 neutropenia and gastrointestinal reactions compared with sCCRT and RT alone. No significant difference of toxicities was observed between sCCRT and RT alone. Our results demonstrated that CCRT in elderly patients had significant survival benefit compared to RT alone, especially using Single oral agent. sCCRT had less toxicities compared to dCCRT, and the toxicity was similar to RT alone. GTV dose ≥ 56 Gy and SIB technique were optimal approaches for radiotherapy.
关于老年食管鳞癌(ESCC)的报道数据相当有限,缺乏指导老年食管癌患者治疗决策的信息。本研究旨在确定单纯放疗(RT)或同步放化疗(CCRT)治疗老年食管鳞状细胞癌(ESCC)的疗效及最佳治疗方法的相关因素。本研究纳入了中国一家机构的184例年龄≥70岁的I - III期老年ESCC患者,这些患者接受了口服单药CCRT(sCCRT)、双药CCRT(dCCRT)或单纯RT治疗。放疗采用调强放射治疗(IMRT)或容积调强弧形治疗(VMAT)。对大体肿瘤体积(GTV)进行剂量递增时采用序贯或同步整合加量(SIB)方法。毒性反应根据放射肿瘤学组的标准进行评估。对生存和失败模式进行统计分析。中位随访时间为15.5个月,2年和3年的估计总生存率(OS)分别为43.5%和35.2%。T和N分期、GTV剂量(临界值56Gy)、同步整合加量(SIB)技术和CCRT是预后的显著预测因素。与单纯RT相比,sCCRT与更高的OS、局部区域无复发生存率(LRFS)和无病生存率(DFS)显著相关,且sCCRT与dCCRT之间未观察到差异。44%的患者出现治疗失败,其中65.4%发生局部失败。81.3%的局部失败发生在GTV,70.6%的区域失败发生在放射野外。与sCCRT和单纯RT相比,dCCRT是≥2级中性粒细胞减少和胃肠道反应的唯一独立预测因素。sCCRT与单纯RT之间未观察到毒性反应的显著差异。我们的结果表明,与单纯RT相比,老年患者接受CCRT有显著的生存获益,尤其是使用单口服药物时。与dCCRT相比,sCCRT的毒性较小,且毒性与单纯RT相似。GTV剂量≥56Gy和SIB技术是放疗的最佳方法。